MMV183

MMV183

Translational
-
Preclinical
(TropIQ)
Asexual blood stages
Transmission reduction
Product vision
  • Uncomplicated malaria treatment
  • Under assessment for severe malaria
MOA
  • Novel mechanism - inhibition of acetylCoA synthetase
Key features

  • Predicted 100 mg single-dose in human

  • Transmission-blocking activity
Challenges
  • Development of an injectable formulation for  Intramuscular and intravenous delivery
Status

  • Preclinical development – Good Laboratory Practice general toxicology and safety pharmacology completed

  • CMC – Good Manufacturing Practice drug substance completed
Next milestone
  • First-in-human phase I clinical study (parenteral delivery)
Previously
  • Discovery collaboration with TropIQ
Project Director
  • Dr Andrew Slade